表紙
市場調查報告書

開發藥劑中人工智能 (AI)的全球市場預測 2024年:機器學習及深度學習

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

出版商 MarketsandMarkets 商品編碼 917077
出版日期 內容資訊 英文 156 Pages
訂單完成後即時交付
價格
Back to Top
開發藥劑中人工智能 (AI)的全球市場預測 2024年:機器學習及深度學習 Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024
出版日期: 2019年11月19日內容資訊: 英文 156 Pages
簡介

全球開發藥劑中人工智能 (AI) 市場規模預測將從2019年的2億5,900萬美元擴大到2024年14億3,400萬美元,在預測期間中預計將為40.8%的年複合成長率 (CAGR) 。該市場的成長主要由於藥物研發、開發成本的管理及藥物研發花費的整體期間的必要性,雲端型應用服務的引進擴大及即將產生的暢銷醫藥品的專利產額而受到促進。另一方面,藥物研發領域的資料集不足及技術純熟勞工的不足,成為對該市場的成長來說的課題。

本報告涵括全球開發藥劑中人工智能 (AI) 市場,提供服務,技術,用途,終端用戶及地區等各市場區隔之市場現況與展望相關調查分析,競爭環境分析,以及主要企業簡介等資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 開發藥劑中人工智能 (AI) 市場概要
  • 開發藥劑中人工智能 (AI) 市場:各提供物/服務
  • 機器學習開發藥劑中人工智能 (AI) 市場:各類型、地區
  • 開發藥劑中人工智能 (AI) 市場:地區的成長機會

第5章 市場概要、產業趨勢

  • 簡介
  • 市場動態
    • 促進要素
    • 阻礙要素
    • 機會
    • 課題

第6章 開發藥劑中人工智能 (AI) 市場:各類服務

  • 簡介
  • 軟體
  • 服務

第7章 開發藥劑中人工智能 (AI) 市場:各技術

  • 簡介
  • 機器學習
    • 研究中心、醫藥品企業的ML的引進擴大支撐該市場區隔成長
    • 深度學習
    • 有教師學習
    • 強化學習
    • 沒有教師學習
    • 其他機器學習技術
  • 其他技術

第8章 開發藥劑中人工智能 (AI) 市場:各用途

  • 簡介
  • 癌症免疫療法
  • 神經退化性疾病
  • 心血管疾病
  • 代謝疾病
  • 其他的用途

第9章 開發藥劑中人工智能 (AI) 市場:各終端用戶

  • 簡介
  • 醫藥品、生物科技企業
  • CRO (醫藥品臨床研究委外機構)
  • 研究中心及大學、政府機關

第10章 開發藥劑中人工智能 (AI) 市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第11章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭領導製圖
  • 競爭情形、趨勢

第12章 企業簡介

  • MICROSOFT CORPORATION
  • NVIDIA CORPORATION
  • IBM CORPORATION
  • GOOGLE (A SUBSIDIARY OF ALPHABET INC.)
  • ATOMWISE, INC.
  • DEEP GENOMICS
  • CLOUD PHARMACEUTICALS, INC.
  • INSILICO MEDICINE
  • BENEVOLENTAI
  • EXSCIENTIA
  • CYCLICA
  • BIOAGE
  • NUMERATE
  • NUMEDII, INC.
  • ENVISAGENICS
  • TWOXAR, INCORPORATED
  • OWKIN, INC.
  • XTALPI, INC.
  • VERGE GENOMICS
  • BERG LLC

第13章 附錄

目錄
Product Code: HIT 7445

"Growing number of cross-industry collaborations and partnerships and the need to control drug discovery & development costs and reduce the overall time taken in this process are the key factors driving the AI in the drug discovery market.".

The global AI in the drug discovery market is projected to reach USD 1,434 million by 2024 from USD 259 million in 2019, at a CAGR of 40.8% during the forecast period. Growth in this market is mainly driven by growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications & services, and the impending patent expiry of blockbuster drugs. On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

"The immuno-oncology segment accounted for the largest share in 2019."

Based on application, the artificial intelligence in the drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of 44.6% of the AI in the drug discovery market in 2018, owing to the increasing demand for effective cancer drugs. Neurodegenerative diseases form the fastest-growing application segment, with a CAGR of 42.9% during the forecast period. The ability of AI to discover drugs for complex diseases and the emphasis of market players on providing AI-based platforms for neurological diseases are responsible for the fast growth of this application segment.

"The Research centers and academic & government institutes segment to register the highest growth rate in the forecast period."

Based on end-user, the AI in the drug discovery market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and research centers and academic, & government institutes. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in the drug discovery market. AI and machine learning to allow pharmaceutical companies to operate more efficiently and substantially improve success rates at the early stages of drug development. This is one of the major factors driving the growth of this market. Research centers and academic & government institutes are expected to show the highest growth of 43.6%.during the forecast period. The growth of the CROs segment is tied to that of pharmaceutical & biotechnology companies, as the rise in research and production activity will ensure sustained demand for contract services.

"North America to be the largest and the fastest-growing regional market."

North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. In the North American market, the US is a significant contributor. Also, prominent AI technology providers, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their strong presence is a key contributor to market growth. Other drivers include the well-established pharmaceutical industry, high focus on R&D & substantial investment, and the presence of globally leading pharmaceutical companies. These are some of the major factors responsible for the large share and high growth rate of this market.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 (28%), Tier 2 (42%), and Tier 3 (30%)
  • By Designation: C-level (30%), D-level (34%), and Others (36%)
  • By Region: North America (46%), Europe (25%), Asia (18%), and the RoW (11%)

List of Companies Profiled in the Report:

  • IBM Corporation (US)
  • Microsoft (US), Google (US)
  • NVIDIA Corporation (US)
  • Atomwise, Inc. (US)
  • Deep Genomics (Canada)
  • Cloud Pharmaceuticals (US)
  • Insilico Medicine (US)
  • Benevolent AI (UK)
  • Exscientia (UK)
  • Cyclica (Canada)
  • BIOAGE (US)
  • Numerate (US)
  • Numedii (US)
  • Envisagenics (US)
  • twoXAR (US)
  • OWKIN, Inc. (US)
  • XtalPi (US)
  • Verge Genomics (US)
  • Berg LLC (US)

Research Coverage:

This report provides a study of the AI in the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments, such as offering, technology, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall AI in drug discovery market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY SOURCES
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW
  • 4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2019-2024)
  • 4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2018)
  • 4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Growing number of cross-industry collaborations and partnerships
      • 5.2.1.2 Need to control drug discovery & development costs and reduce time
      • 5.2.1.3 Patent expiry
    • 5.2.2 MARKET OPPORTUNITIES
      • 5.2.2.1 Growing biotechnology industry
      • 5.2.2.2 Emerging markets
    • 5.2.3 MARKET CHALLENGES
      • 5.2.3.1 Limited availability of data sets

6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 SOFTWARE
    • 6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING MARKET GROWTH
  • 6.3 SERVICES
    • 6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD

7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 MACHINE LEARNING
    • 7.2.1 INCREASING ADOPTION OF ML BY RESEARCH CENTERS & PHARMACEUTICAL COMPANIES TO SUPPORT THE GROWTH OF THIS SEGMENT
    • 7.2.2 DEEP LEARNING
    • 7.2.3 SUPERVISED LEARNING
    • 7.2.4 REINFORCEMENT LEARNING
    • 7.2.5 UNSUPERVISED LEARNING
    • 7.2.6 OTHER MACHINE LEARNING TECHNOLOGIES
  • 7.3 OTHER TECHNOLOGIES

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 IMMUNO-ONCOLOGY
    • 8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE IN THE SUPPLY OF CANCER DRUGS ARE THE KEY FACTORS DRIVING MARKET GROWTH
  • 8.3 NEURODEGENERATIVE DISEASES
    • 8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT
  • 8.4 CARDIOVASCULAR DISEASES
    • 8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING MARKET GROWTH
  • 8.5 METABOLIC DISEASES
    • 8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT
  • 8.6 OTHER APPLICATIONS

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAVE DRAWN END-USER ATTENTION TO AI
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 GROWING TREND OF OUTSOURCING PROVIDES SIGNIFICANT OPPORTUNITIES FOR CROS
  • 9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
    • 9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
      • 10.2.1.1 US
        • 10.2.1.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US
      • 10.2.1.2 Canada
        • 10.2.1.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support the market in Canada
      • 10.2.1.3 Mexico
        • 10.2.1.3.1 Government initiatives will support market growth in Mexico
  • 10.3 EUROPE
    • 10.3.1 UK
      • 10.3.1.1 The UK holds the largest share of the European market
    • 10.3.2 GERMANY
      • 10.3.2.1 Government support and favorable training programs are major market drivers in Germany
    • 10.3.3 FRANCE
      • 10.3.3.1 Strong government support and favorable strategies & initiatives form key drivers of the market in France
    • 10.3.4 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 JAPAN
      • 10.4.1.1 Japan dominates the APAC market for AI in drug discovery
    • 10.4.2 CHINA
      • 10.4.2.1 Growing CMOs market and cross-industry collaborations are factors responsible for the growth of the market in China
    • 10.4.3 INDIA
      • 10.4.3.1 Steady adoption of AI technologies will drive market growth in India
    • 10.4.4 REST OF ASIA PACIFIC
  • 10.5 REST OF THE WORLD

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET SHARE ANALYSIS
  • 11.3 COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1 VISIONARY LEADERS
    • 11.3.2 DYNAMIC DIFFERENTIATORS
    • 11.3.3 INNOVATORS
    • 11.3.4 EMERGING COMPANIES
  • 11.4 COMPETITIVE SITUATION AND TRENDS
    • 11.4.1 PRODUCT LAUNCHES AND ENHANCEMENTS
    • 11.4.2 EXPANSIONS
    • 11.4.3 ACQUISITIONS
    • 11.4.4 OTHER STRATEGIES

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 12.1 MICROSOFT CORPORATION
  • 12.2 NVIDIA CORPORATION
  • 12.3 IBM CORPORATION
  • 12.4 GOOGLE (A SUBSIDIARY OF ALPHABET INC.)
  • 12.5 ATOMWISE, INC.
  • 12.6 DEEP GENOMICS
  • 12.7 CLOUD PHARMACEUTICALS, INC.
  • 12.8 INSILICO MEDICINE
  • 12.9 BENEVOLENTAI
  • 12.10 EXSCIENTIA
  • 12.11 CYCLICA
  • 12.12 BIOAGE
  • 12.13 NUMERATE
  • 12.14 NUMEDII, INC.
  • 12.15 ENVISAGENICS
  • 12.16 TWOXAR, INCORPORATED
  • 12.17 OWKIN, INC.
  • 12.18 XTALPI, INC.
  • 12.19 VERGE GENOMICS
  • 12.20 BERG LLC

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2017-2019)
  • TABLE 2: INDICATIVE LIST OF DRUGS LOSING PATENT IN 2019
  • TABLE 3: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 4: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 5: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 6: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 7: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 8: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 9: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 10: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 11: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 12: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 13: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 14: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 15: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 16: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 17: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 18: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 19: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 20: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 21: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 22: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 24: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 25: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 26: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 28: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 29: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 30: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 31: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 32: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 33: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 34: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 35: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 36: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 37: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 38: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 39: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 40: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 41: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 42: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 43: INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT
  • TABLE 44: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 46: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 47: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 48: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 49: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 50: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 51: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 52: INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
  • TABLE 53: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 54: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 55: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 56: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 57: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 58: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 59: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 60: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 61: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 62: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 63: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 64: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 65: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 66: INDICATIVE LIST OF DEVELOPMENTS
  • TABLE 67: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 68: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 69: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 70: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 71: INDICATIVE LIST OF COLLABORATIONS WITH CROS
  • TABLE 72: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 73: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 74: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 75: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 76: INDICATIVE LIST OF RESEARCH COLLABORATIONS
  • TABLE 77: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 78: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, 2017-2024 (USD MILLION)
  • TABLE 79: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, 2017-2024 (USD MILLION)
  • TABLE 80: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, 2017-2024 (USD MILLION)
  • TABLE 81: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 82: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 83: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 84: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 85: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 86: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 87: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
  • TABLE 88: US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 89: US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 90: US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 91: US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 92: CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 93: CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 94: CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 95: CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 96: MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 97: MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 98: MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 99: MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 100: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 101: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 102: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 103: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 104: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 105: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
  • TABLE 106: UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 107: UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 108: UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 109: UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 110: GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 111: GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 112: GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 113: GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 114: FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 115: FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 116: FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 117: FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 118: ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 119: ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 120: ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 121: ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 122: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 123: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 124: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 125: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 126: APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 127: JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 128: JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 129: JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 130: JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 131: CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 132: CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 133: CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 134: CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 135: INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 136: INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 137: INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 138: INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 139: ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 140: ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 141: ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 142: ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 143: ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION)
  • TABLE 144: ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 145: ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 146: ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 147: PRODUCT LAUNCHES AND ENHANCEMENTS, 2016-2019
  • TABLE 148: EXPANSIONS, 2016-2019
  • TABLE 149: ACQUISITIONS, 2016-2019
  • TABLE 150: OTHER STRATEGIES, 2016-2019

LIST OF FIGURES

  • FIGURE 1: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2019-2024
  • FIGURE 9: ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION)
  • FIGURE 10: ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
  • FIGURE 11: GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
  • FIGURE 12: NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A MAJOR FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS
  • FIGURE 13: SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 15: NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY
  • FIGURE 16: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
  • FIGURE 18: EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
  • FIGURE 19: KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES
  • FIGURE 20: MARKET EVOLUTION FRAMEWORK
  • FIGURE 21: AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
  • FIGURE 22: COMPETITIVE LEADERSHIP MAPPING OF THE AI IN DRUG DISCOVERY MARKET
  • FIGURE 23: MICROSOFT CORPORATION: COMPANY SNAPSHOT
  • FIGURE 24: NVIDIA CORPORATION: COMPANY SNAPSHOT
  • FIGURE 25: IBM CORPORATION: COMPANY SNAPSHOT
  • FIGURE 26: ALPHABET: COMPANY SNAPSHOT
Back to Top